A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT05164133
- Phase
- PHASE1
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tocilizumab — DRUGParticipants will receive intravenous (IV) tocilizumab
Study Details
This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of tocilizumab (TCZ) for the treatment of pediatric patients from birth to less than 18 years old hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
Key Dates
- Start date
- Jun 10, 2022
- Status verified
- Apr 2024
- Primary completion
- Mar 27, 2024
- Completion
- Mar 27, 2024
Study Design
- Enrollment
- 2 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: All ParticipantsParticipants who are hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation will receive a single dose of TCZ on Day 1, with the option to receive a second dose 8-24 hours later if clinically indicated.
Primary Outcome Measure
Serum concentration of TCZ [ Time Frame: Through Day 28 ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Reagan UCLA Medical Center | Los Angeles | California | 90095 | - |
| The University of Chicago | Chicago | Illinois | 60637 | - |
| Central Michigan University College of Medicine | Mount Pleasant | Michigan | 48858-3803 | - |
| Feinstein Institute for Medical Research | Manhasset | New York | 11030 | - |
| University Hospitals Cleveland Medical Center, Rainbow Babies and Childrens Hospital | Cleveland | Ohio | 44106-2624 | - |
| UT Physicians - Pediatric Center - Texas Medical Center | Houston | Texas | 77030-3005 | - |
| University of Utah - PPDS | Salt Lake City | Utah | 84108-1287 | - |
Find similar trials in Los Angeles, CA
By condition
By specialty
By research site
Reagan UCLA Medical Center· Los Angeles, CAThe University of Chicago· Chicago, ILCentral Michigan University College of Medicine· Mount Pleasant, MIFeinstein Institute for Medical Research· Manhasset, NYUniversity Hospitals Cleveland Medical Center, Rainbow Babies and Childrens Hospital· Cleveland, OHUT Physicians - Pediatric Center - Texas Medical Center· Houston, TX
Related Studies
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT StudyPHASE3 · Recruiting · Ansun Biopharma, Inc. · Duarte, California
- Impact of the Coronavirus (COVID-19) on Patients With CancerRecruiting · Stanford University · Stanford, California
- A Study to Explore the Role of Gut Flora in COVID-19 InfectionRecruiting · ProgenaBiome · Ventura, California
- ARMOR Study: COVID-19 Seroprevalence Among Healthcare WorkersRecruiting · Columbia University · New York, New York